SEA BCMA
Alternative Names: SEA-BCMA; SGN-BCMALatest Information Update: 04 Jul 2025
At a glance
- Originator Seattle Genetics
- Developer Seagen
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple myeloma
Most Recent Events
- 01 Jul 2025 SpringWorks Therapeutics has been acquired by Merck KGaA
- 28 Jan 2025 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy, Second-line therapy or greater) in USA (IV, Infusion)
- 28 Jan 2025 No recent reports of development identified for phase-I development in Multiple-myeloma(Monotherapy, Second-line therapy or greater) in USA (IV, Infusion)